Biogen to Cut Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Biogen to Cut Jobs

ePT--the Electronic Newsletter of Pharmaceutical Technology

Biogen to Cut Jobs

Biogen Idec (Boston, MA) said last Thursday that it would lay off approximately 17% of its workforce to reduce annual operating costs by $200–300 million.

The downsizing will be part of a restructuring plan conceived after reviews of business processes, geographic locations, and staffing. Cuts will be made at the managerial and staff level, and are expected to equate to approximately 650 jobs, mostly in the San Diego, California, area, and at the company's manufacturing operations at Research Triangle Park, North Carolina.

In addition, the company plans to sell its NICO clinical manufacturing plant in San Diego and property in Oceanside, California. Also on the chopping block is the psoriasis drug, "Amevive," which had revenue of $43 million in 2004. Biogen expects the plan to take effect by the end of the year.

Biogen Idec said that it is considering using the additional funds for new product opportunities and 'the acquisition of products and companies, as well as expanding collaborative research with academic institutions and teaching hospitals."

In related news, Biogen also announced that Michael Gilman, executive vice-president of research, is leaving the company, effective Nov. 8. Alphonse Galdes, vice-president of drug discovery, and Rainer Fuchs, vice-president of research informatics and operations, will take his place in the interim.

–George Koroneos

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here